Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with
about a third of cases being genetic. Most of this genetic component is accounted for by …

Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial
fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process …

Objective We tested the hypothesis that plasma neurofilament light chain (NfL) identifies
asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)–causing mutations …

The frontotemporal dementia (FTD) spectrum of neurodegenerative disorders includes a
heterogeneous group of conditions. However, following on from a series of important molecular …

Unlike familial Alzheimer’s disease, we have been unable to accurately predict symptom
onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a …

Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic
frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN…

Human prion diseases are remarkable for long incubation times followed typically by rapid
clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are …

Introduction Synapse dysfunction is emerging as an early pathological event in frontotemporal
dementia (FTD), however biomarkers are lacking. We aimed to investigate the value of …

Several CSF and blood biomarkers for genetic frontotemporal dementia have been proposed,
including those reflecting neuroaxonal loss (neurofilament light chain and phosphorylated …

The outer membrane of gram-negative bacteria is composed of phospholipids in the inner
leaflet and lipopolysaccharides (LPS) in the outer leaflet. LPS is an endotoxin that elicits a …